clinical trial · NCT04433585
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
Systemic Lupus ErythematosusLY3471851Placebo
brief summary
The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).
started
Aug 19, 2020
primary completion
Jan 10, 2023
completion
Feb 16, 2023
last updated
Apr 23, 2024
detailed description
LY3471851 is a potential first-in-class therapeutic that may address an underlying immune system imbalance in people with many autoimmune conditions. It targets the interleukin (IL-2) receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells. By activating these cells, LY3471851 may act to bring the immune system back into balance.
official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol